{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:23:14Z","timestamp":1773901394040,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801604"],"award-info":[{"award-number":["81801604"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91442120, 81771740"],"award-info":[{"award-number":["91442120, 81771740"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7184251"],"award-info":[{"award-number":["7184251"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Overlapping Sjogren\u2019s syndrome (SS) is not uncommon in rheumatoid arthritis (RA) and considered as a probable detrimental factor of RA. But data on the impact of overlapping SS on RA therapeutic response is limited. Our current study aimed to identify the effect in a real-world cohort from 2009 to 2019.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The medical records of RA patients who visited the rheumatology clinic of our medical center from 2009 to 2019 were reviewed. Their composite disease activity scores at each follow-up point were collected. The therapeutic response between RA patients with SS (RA-SS) and without (RA-noSS) was compared. To correct confounders which may affect the therapeutic response, both propensity score matched and unmatched cohorts were analyzed by using the Cox proportional hazards model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 1099 RA patients, 129 (11.7%) overlapped with SS were validated by positive anti-SSA or a minor salivary gland biopsy with histological changes suggestive of SS. After propensity score matching based on their baseline characteristics, 126 of 129 RA-SS and 126 of 970 RA-noSS patients were statistically extracted. Overlapping SS was associated with a 29%, 26%, 18%, and 22% lower probability of reaching remission defined by DAS28-ESR, DAS28-CRP, SDAI, and CDAI in RA patients, respectively. Similar decreased probability of reaching low disease activity was also observed. Although ESR was most significantly affected (HR 0.69, 95% CI 0.61\u20130.79), other component of composite RA disease activity score was also affected by overlapping SS. Stratification by age, RF\/ACPA status, or baseline DAS28-CRP was not associated with change of results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Overlapping SS is associated with lower probability of reaching remission or low disease activity in RA patients and should be regarded as one of the poor prognostic factors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-020-02189-w","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T17:02:34Z","timestamp":1588352554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Overlapping Sjogren\u2019s syndrome reduces the probability of reaching target in rheumatoid arthritis patients: a propensity score matched real-world cohort from 2009 to 2019"],"prefix":"10.1186","volume":"22","author":[{"given":"Huijuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoze","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6925-4960","authenticated-orcid":false,"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"issue":"13","key":"2189_CR1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. Jama. 2018;320(13):1360\u201372.","journal-title":"Jama."},{"issue":"3","key":"2189_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1756-185X.2012.01717.x","volume":"15","author":"HJ Haga","year":"2012","unstructured":"Haga HJ, Naderi Y, Moreno AM, Peen E. A study of the prevalence of sicca symptoms and secondary Sjogren\u2019s syndrome in patients with rheumatoid arthritis, and its association to disease activity and treatment profile. Int J Rheum Dis. 2012;15(3):284\u20138.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"2189_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","volume":"76","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sjogren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9\u201316.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2189_CR4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1136\/ard.60.12.1103","volume":"60","author":"IM Gilboe","year":"2001","unstructured":"Gilboe IM, Kvien TK, Uhlig T, Husby G. Sicca symptoms and secondary Sjogren\u2019s syndrome in systemic lupus erythematosus: comparison with rheumatoid arthritis and correlation with disease variables. Ann Rheum Dis. 2001;60(12):1103\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2189_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/rheumatology\/keu400","volume":"54","author":"LE Brown","year":"2015","unstructured":"Brown LE, Frits ML, Iannaccone CK, Weinblatt ME, Shadick NA, Liao KP. Clinical characteristics of RA patients with secondary SS and association with joint damage. Rheumatology (Oxford). 2015;54(5):816\u201320.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"2189_CR6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/ard.62.9.897","volume":"62","author":"L Carmona","year":"2003","unstructured":"Carmona L, Gonzalez-Alvaro I, Balsa A, Angel Belmonte M, Tena X, Sanmarti R. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis. 2003;62(9):897\u2013900.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2189_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/PL00006853","volume":"19","author":"MA Cimmino","year":"2000","unstructured":"Cimmino MA, Salvarani C, Macchioni P, Montecucco C, Fossaluzza V, Mascia MT, et al. Extra-articular manifestations in 587 Italian patients with rheumatoid arthritis. Rheumatol Int. 2000;19(6):213\u20137.","journal-title":"Rheumatol Int"},{"issue":"3","key":"2189_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0049-0172(95)80032-8","volume":"25","author":"L Massardo","year":"1995","unstructured":"Massardo L, Aguirre V, Garcia ME, Cervila V, Nicovani S, Gonzalez A, et al. Clinical expression of rheumatoid arthritis in Chilean patients. Semin Arthritis Rheum. 1995;25(3):203\u201313.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"2189_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3109\/14397595.2013.843765","volume":"24","author":"H Tsuboi","year":"2014","unstructured":"Tsuboi H, Asashima H, Takai C, Hagiwara S, Hagiya C, Yokosawa M, et al. Primary and secondary surveys on epidemiology of Sjogren\u2019s syndrome in Japan. Mod Rheumatol. 2014;24(3):464\u201370.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"2189_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1053\/sarh.2002.31725","volume":"31","author":"JP Ioannidis","year":"2002","unstructured":"Ioannidis JP, Tarassi K, Papadopoulos IA, Voulgari PV, Boki KA, Papasteriades CA, et al. Shared epitopes and rheumatoid arthritis: disease associations in Greece and meta-analysis of Mediterranean European populations. Semin Arthritis Rheum. 2002;31(6):361\u201370.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"2189_CR11","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/rheumatology\/kes374","volume":"52","author":"J He","year":"2013","unstructured":"He J, Ding Y, Feng M, Guo J, Sun X, Zhao J, et al. Characteristics of Sjogren\u2019s syndrome in rheumatoid arthritis. Rheumatology (Oxford). 2013;52(6):1084\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"2189_CR12","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/1756-185X.13017","volume":"20","author":"K Santosh","year":"2017","unstructured":"Santosh K, Dhir V, Singh S, Sood A, Gupta A, Sharma A, et al. Prevalence of secondary Sjogren\u2019s syndrome in Indian patients with rheumatoid arthritis: a single-center study. Int J Rheum Dis. 2017;20(7):870\u20134.","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"2189_CR13","first-page":"448","volume":"54","author":"A Hajiabbasi","year":"2016","unstructured":"Hajiabbasi A, Shenavar Masooleh I, Alizadeh Y, Banikarimi AS, Ghavidel PP. Secondary Sjogren's syndrome in 83 patients with rheumatoid arthritis. Acta Med Iran. 2016;54(7):448\u201353.","journal-title":"Acta Med Iran"},{"issue":"4","key":"2189_CR14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2189_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41584-019-0170-5","volume":"15","author":"R van Vollenhoven","year":"2019","unstructured":"van Vollenhoven R. Treat-to-target in rheumatoid arthritis - are we there yet? Nat Rev Rheumatol. 2019;15(3):180\u20136.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"2189_CR16","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2189_CR17","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1136\/annrheumdis-2018-213502","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, van Vollenhoven RF, Florentinus S, Chen S, Suboticki JL, Kavanaugh A. Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. Ann Rheum Dis. 2018;77(11):1566\u201372.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2189_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315\u201324.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2189_CR19","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2189_CR20","first-page":"820","volume":"36","author":"W Xie","year":"2018","unstructured":"Xie W, Li J, Zhang X, Li G, Hao Y, Zhao J, et al. Trends in the activity of rheumatoid arthritis as the consequence of treat-to-target strategy: eight-year data from 2009 to 2016. Clin Exp Rheumatol. 2018;36(5):820\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"2189_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivariate Behav Res"},{"issue":"1","key":"2189_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B","volume":"43","author":"AJ MacGregor","year":"2000","unstructured":"MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 2000;43(1):30\u20137.","journal-title":"Arthritis Rheum"},{"issue":"25","key":"2189_CR23","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1093\/hmg\/ddu387","volume":"23","author":"Y Okada","year":"2014","unstructured":"Okada Y, Kim K, Han B, Pillai NE, Ong RT, Saw WY, et al. Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations. Hum Mol Genet. 2014;23(25):6916\u201326.","journal-title":"Hum Mol Genet"},{"issue":"8","key":"2189_CR24","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1002\/art.11103","volume":"48","author":"JE Gottenberg","year":"2003","unstructured":"Gottenberg JE, Busson M, Loiseau P, Cohen-Solal J, Lepage V, Charron D, et al. In primary Sjogren\u2019s syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum. 2003;48(8):2240\u20135.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2189_CR25","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJMoa073003","volume":"357","author":"EF Remmers","year":"2007","unstructured":"Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007;357(10):977\u201386.","journal-title":"N Engl J Med"},{"issue":"6","key":"2189_CR26","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/art.40040","volume":"69","author":"KE Taylor","year":"2017","unstructured":"Taylor KE, Wong Q, Levine DM, McHugh C, Laurie C, Doheny K, et al. Genome-wide association analysis reveals genetic heterogeneity of Sjogren\u2019s syndrome according to ancestry. Arthritis Rheumatol. 2017;69(6):1294\u2013305.","journal-title":"Arthritis Rheumatol"},{"key":"2189_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1741-7015-12-35","volume":"12","author":"TT Glant","year":"2014","unstructured":"Glant TT, Mikecz K, Rauch TA. Epigenetics in the pathogenesis of rheumatoid arthritis. BMC Med. 2014;12:35.","journal-title":"BMC Med"},{"key":"2189_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fgene.2019.00223","volume":"10","author":"S Chen","year":"2019","unstructured":"Chen S, Pu W, Guo S, Jin L, He D, Wang J. Genome-wide DNA methylation profiles reveal common epigenetic patterns of interferon-related genes in multiple autoimmune diseases. Front Genet. 2019;10:223.","journal-title":"Front Genet"},{"key":"2189_CR29","doi-asserted-by":"crossref","unstructured":"Imgenberg-Kreuz J, Rasmussen A, Sivils K, Nordmark G. Genetics and epigenetics in primary Sjogren\u2019s syndrome. Rheumatology (Oxford); 2019.","DOI":"10.1093\/rheumatology\/key330"},{"issue":"6","key":"2189_CR30","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.autrev.2009.01.008","volume":"8","author":"C Carissimi","year":"2009","unstructured":"Carissimi C, Fulci V, Macino G. MicroRNAs: novel regulators of immunity. Autoimmun Rev. 2009;8(6):520\u20134.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"2189_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1365-3083.2010.02383.x","volume":"71","author":"L Li","year":"2010","unstructured":"Li L, Chen XP, Li YJ. MicroRNA-146a and human disease. Scand J Immunol. 2010;71(4):227\u201331.","journal-title":"Scand J Immunol"},{"issue":"7","key":"2189_CR32","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1002\/eji.201040757","volume":"41","author":"KM Pauley","year":"2011","unstructured":"Pauley KM, Stewart CM, Gauna AE, Dupre LC, Kuklani R, Chan AL, et al. Altered miR-146a expression in Sjogren\u2019s syndrome and its functional role in innate immunity. Eur J Immunol. 2011;41(7):2029\u201339.","journal-title":"Eur J Immunol"},{"issue":"10","key":"2189_CR33","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1084\/jem.20160792","volume":"213","author":"EM Tan","year":"2016","unstructured":"Tan EM, Smolen JS. Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. J Exp Med. 2016;213(10):1937\u201350.","journal-title":"J Exp Med"},{"issue":"5","key":"2189_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/BOR.0000000000000622","volume":"31","author":"M Maslinska","year":"2019","unstructured":"Maslinska M. The role of Epstein-Barr virus infection in primary Sjogren\u2019s syndrome. Curr Opin Rheumatol. 2019;31(5):475\u201383.","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"2189_CR35","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41588-018-0102-3","volume":"50","author":"JB Harley","year":"2018","unstructured":"Harley JB, Chen X, Pujato M, Miller D, Maddox A, Forney C, et al. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat Genet. 2018;50(5):699\u2013707.","journal-title":"Nat Genet"},{"issue":"1","key":"2189_CR36","first-page":"70","volume":"35","author":"P de Pablo","year":"2008","unstructured":"de Pablo P, Dietrich T, McAlindon TE. Association of periodontal disease and tooth loss with rheumatoid arthritis in the US population. J Rheumatol. 2008;35(1):70\u20136.","journal-title":"J Rheumatol"},{"key":"2189_CR37","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.5109","volume":"6","author":"TC Lin","year":"2018","unstructured":"Lin TC, Tseng CF, Wang YH, Yu HC, Chang YC. Patients with chronic periodontitis present increased risk for primary Sjogren syndrome: a nationwide population-based cohort study. PeerJ. 2018;6:e5109.","journal-title":"PeerJ."},{"key":"2189_CR38","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/B978-0-323-09138-1.00092-9","volume-title":"Rheumatology","author":"JS Hill Gaston","year":"2015","unstructured":"Hill Gaston JS. Cellular immunity in rheumatoid arthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 6th ed. Philadelphia: Elsevier; 2015. p. 758\u201363.","edition":"6"},{"key":"2189_CR39","doi-asserted-by":"crossref","unstructured":"Verstappen GM, Kroese FGM, Bootsma H. T cells in primary Sjogren\u2019s syndrome: targets for early intervention. Rheumatology (Oxford). 2019.","DOI":"10.1093\/rheumatology\/kez004"},{"issue":"6","key":"2189_CR40","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3109\/14397595.2016.1158773","volume":"26","author":"H Tsuboi","year":"2016","unstructured":"Tsuboi H, Matsumoto I, Hagiwara S, Hirota T, Takahashi H, Ebe H, et al. Effectiveness of abatacept for patients with Sjogren\u2019s syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjogren\u2019s syndrome Endocrinopathy) trial. Mod Rheumatol. 2016;26(6):891\u20139.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"2189_CR41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.rdc.2016.03.001","volume":"42","author":"G Nocturne","year":"2016","unstructured":"Nocturne G, Cornec D, Seror R, Mariette X. Use of biologics in Sjogren\u2019s syndrome. Rheum Dis Clin N Am. 2016;42(3):407\u201317.","journal-title":"Rheum Dis Clin N Am"},{"issue":"10","key":"2189_CR42","doi-asserted-by":"publisher","first-page":"17050","DOI":"10.1002\/jcp.28445","volume":"234","author":"AG Shabgah","year":"2019","unstructured":"Shabgah AG, Shariati-Sarabi Z, Tavakkol-Afshari J, Mohammadi M. The role of BAFF and APRIL in rheumatoid arthritis. J Cell Physiol. 2019;234(10):17050\u201363.","journal-title":"J Cell Physiol"},{"issue":"6","key":"2189_CR43","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S","volume":"44","author":"GS Cheema","year":"2001","unstructured":"Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44(6):1313\u20139.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2189_CR44","first-page":"1256","volume":"35","author":"S Bosello","year":"2008","unstructured":"Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol. 2008;35(7):1256\u201364.","journal-title":"J Rheumatol"},{"issue":"5","key":"2189_CR45","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1756-185X.2012.01814.x","volume":"15","author":"Y Geng","year":"2012","unstructured":"Geng Y, Zhang ZL. Comparative study on the level of B lymphocyte stimulator (BlyS) and frequency of lymphocytes between sero-negative and sero-positive rheumatoid arthritis patients. Int J Rheum Dis. 2012;15(5):478\u201385.","journal-title":"Int J Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02189-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02189-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02189-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T13:11:30Z","timestamp":1620047490000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02189-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2189"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02189-w","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,1]]},"assertion":[{"value":"21 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Research Ethics Committee, and all patients received informed consent for data collection of their medical records.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}